All In Biotech

Drug Trial Radar · NCT07643623

Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma

A Randomized, Double-Blind, Phase II/III Clinical Study of the Efficacy and Safety of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Perioperative Treatment of Resectable Gastric/Gastroesophageal Junction Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 720 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

720

Planned (sponsor's estimate)

Start

Jul 31, 2026

Primary completion

Dec 31, 2031

Study completion Dec 31, 2031

Sponsor

Sponsor type
Industry
First posted
Jun 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Randomized, Double-Blind, Phase II/III Clinical Study of the Efficacy and Safety of Sintilimab Combined with Chemotherapy With or Without Ipilimumab N01 in Perioperative Treatment of Resectable Gastric/Gastroesophageal Junction Adenocarcinoma.

Conditions

  • Resectable Gastric/Gastroesophageal Junction Adenocarcinoma

Interventions

  • tegafur, Gimeracil and Oteracil Potassium CapsulesDrug

    40mg/m2, D1-14 BID PO Q3W

  • Sintilimab PlaceboDrug

    200 mg, D1 IV Q3W

  • SintilimabDrug

    200mg D1 IV Q3W

  • Ipilimumab N01Drug

    1mg/kg, D1 IV Q6W

  • Oxaliplatin for injectionDrug

    130 mg/m2 D1 IV Q3W

  • Ipilimumab N01 PlaceboDrug

    1mg/kg, D1 IV Q6W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Major Pathological Response (MPR) rate in Resectable Gastric/Gastroesophageal Junction AdenocarcinomaTime frame: Up to approximately 6 weeks following the beginning of Post-operative Assessment baseline(up to Study 2 years )
  2. Event-Free Survival (EFS)Time frame: Up to approximately 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.